12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ixiaro regulatory update

Intercell disclosed in its 3Q12 earnings that it submitted regulatory applications to FDA and EMA for Ixiaro Japanese Encephalitis (JE) vaccine to include pediatric patients. Intercell also said FDA granted Ixiaro Orphan Drug status in the U.S. for...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >